Results 191 to 200 of about 2,180,698 (310)

Two Approaches of 'Proactive Consultation': Towards Well-Functioning Clinical Ethics Consultation. [PDF]

Asian Bioeth Rev
Kogetsu A, Koimizu J.
europepmc   +1 more source

Participatory development of CURA, a clinical ethics support instrument for palliative care. [PDF]

BMC Med Ethics, 2022
van Schaik MV, Pasman HR, Widdershoven G, Metselaar S.   +3 more
europepmc   +1 more source

The Impact of Tilburg Frailty on Poststroke Fatigue in First‐Ever Stroke Patients: A Cross‐Sectional Study With Unified Measurement Tools and Improved Statistics

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Poststroke fatigue (PSF) and frailty share substantial overlap in their manifestations, yet previous research has yielded conflicting results due to the use of heterogeneous frailty assessment tools. Objective To evaluate the independent impact of frailty on PSF using a unified measurement system (Tilburg Frailty Indicator, TFI ...
Chuan‐Bang Chen, Xiao‐Xue Wang, Shao‐Rui Bao, Sui‐Li Lin, Mei‐Chun Shu, Xi‐Xi Ye, Wen‐Jie Cong   +6 more
wiley   +1 more source

Moral challenges and understanding of clinical ethics in Tanzanian hospitals: Perspectives of healthcare professionals. [PDF]

Dev World Bioeth
Kuhumba SK, A C Molewijk B, Solbakk JH, Mhando NE, Sævareid TJL.   +4 more
europepmc   +1 more source

The Price of Precaution in Clinical Medical Ethics

, 2019
Christian Munthe
openalex   +1 more source

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

A review of clinical ethics consultations in a regional healthcare system over a two-year timeframe. [PDF]

BMC Med Ethics
Anderson G, Hodge J, Fox D, Jutila S, McCarty C.   +4 more
europepmc   +1 more source

On prenatal diagnosis and the decision to continue or terminate a pregnancy in France: a clinical ethics study of unknown moral territories

, 2016
Marie Gaille
openalex   +2 more sources

On the Frontiers of Clinical Research Ethics: Adjusting Norms to Progress [PDF]

, 2017
Jorge Insúa
openalex   +1 more source

SNUPN‐Related Muscular Dystrophy: Novel Phenotypic, Pathological and Functional Protein Insights

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective SNUPN‐related muscular dystrophy or LGMDR29 is a new entity that covers from a congenital or childhood onset pure muscular dystrophy to more complex phenotypes combining neurodevelopmental features, cataracts, or spinocerebellar ataxia. So far, 12 different variants have been described.
Nuria Muelas, Pablo Iruzubieta, Alberto Damborenea, Laura Pérez‐Fernández, Inmaculada Azorín, Juan Carlos Jiménez García, Ana Töpf, Pilar Martí, Lorena Fores‐Toribio, María Manterola, Rosana Blanco‐Mañez, Oihane Pikatza‐Menoio, Sonia Alonso‐Martín, Volker Straub, Aitziber L. Cortajarena, Adolfo López de Munain, David De Sancho, Lorea Blázquez, Juan J. Vilchez   +18 more
wiley   +1 more source